Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of MGB Biopharma.

    Client Virtual Booth

    MGB BIOPHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    MGB Biopharma
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Suite 1-2, Willow House, Strathclyde Business Park, Kestrel View, Bellshill ML4 3PB
    Telephone
    Telephone
    +44 (0)169 846 4224
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mgb-biopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mgb-biopharma-ltd
    Twitter
    Twitter
    https://twitter.com/MGB_Biopharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    MGB Biopharma Announces End-of-Phase 2 Meeting with FDA for MGB-BP-3 as a Treatment for Clostridioides Difficile Infection

    Details:

    Design and endpoints of two prospective Phase 3 studies were approved by the US FDA. The Phase 3 studies will include superiority of MGB-BP-3 against vancomycin in the critical measure of sustained clinical response as one of their endpoints.


    Lead Product(s): Mgb-BP-3

    Therapeutic Area: Infections and Infectious Diseases Product Name: MGB-BP-3

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 27, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3

    Details:

    The study confirms that MGB-BP-3, an antibacterial, has the potential to become the new gold standard, first-line treatment for CDI.


    Lead Product(s): Mgb-BP-3

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 19, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search